Incidence of COVID-19 Following Vaccination in Botswana Against SARS CoV 2
Status:
Completed
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
The AstraZeneca Study is a single-arm, open-label, interventional, Phase 3b study to
determine the incidence of laboratory-confirmed COVID-19 hospitalizations, disease severity,
and deaths and attributable adverse events (AEs) in participants in Botswana given 1 to 2
injections of AZD1222 eight to twelve weeks apart as primary series and/or 1 injection as
booster dose. Length of follow-up will be 6 to 12 months, depending upon at which dose a
participant is enrolled.